TLSA
Tiziana Life Sciences Ltd
$1.82
$0.00(0.00%)
100
Overall
--
Value
100
Tech
--
Quality
Market Cap
$186.14M
Volume
268.77K
52W Range
$0.63 - $2.60
Target Price
$3.00
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | -- | $-27.0K | -- | $-13.3M | -- | -- | -- | ||
| Total Revenue | -- | $-27.0K | -- | $-13.3M | -- | -- | -- | ||
| GROSS PROFIT | |||||||||
| Gross Profit | -- | $-27.0K | -- | $-13.3M | -- | -- | -- | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $5.5M | $3.7M | $19.2M | $13.2M | $13.8M | $18.0M | $15.8M | ||
| Research & Development | $5.5M | $3.7M | $6.0M | $13.2M | $13.0M | $8.1M | $5.2M | ||
| Research Expense | $5.5M | $3.7M | $6.0M | $13.2M | $13.0M | $8.1M | $5.2M | ||
| Selling, General & Administrative | $4.4M | -- | $-2.7M | -- | -- | -- | -- | ||
| Selling & Marketing Expenses | -- | -- | $-2.7M | -- | -- | -- | -- | ||
| General & Administrative Expenses | $4.4M | -- | -- | -- | -- | -- | -- | ||
| Salaries & Wages | $-2.3M | $-3.7M | $13.2M | $855.0K | $-2.0M | -- | -- | ||
| Depreciation & Amortization | $-16.0K | $-245.0K | $-86.0K | $-133.0K | $-50.0K | -- | -- | ||
| Depreciation & Amortization | $-16.0K | $-245.0K | $-86.0K | $-133.0K | $-50.0K | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | $-893.0K | $804.0K | $9.9M | $10.6M | ||
| OPERATING INCOME | |||||||||
| Operating income | $-5.5M | $-3.7M | $-19.2M | $-26.5M | $-13.8M | $-18.0M | $-15.8M | ||
| EBITDA | $-9.9M | $-3.8M | $-24.9M | $-31.1M | $-15.4M | -- | -- | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Income Operating | -- | -- | $-11.2M | $-13.3M | -- | -- | -- | ||
| Intinc | $-12.0K | $-91.0K | $3.2M | $-176.0K | $-7.0K | $1.1M | -- | ||
| Net Non-Operating Interest Income/Expense | $-12.0K | $-91.0K | $3.2M | $-176.0K | $-7.0K | $1.1M | -- | ||
| Gain on Sale of Securities | -- | -- | -- | -- | $-3.6M | -- | -- | ||
| Other Income/Expense | $4.4M | $6.2M | $8.5M | $4.5M | $3.6M | $-742.0K | $952.0K | ||
| Other Special Charges | -- | -- | $3.5M | $893.0K | -- | $1.1M | $814.0K | ||
| SPECIAL ITEMS | |||||||||
| Special Income Charges | -- | -- | $-279.0K | -- | $-869.0K | -- | -- | ||
| Impairment of Capital Assets | -- | -- | $279.0K | -- | $869.0K | -- | -- | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-9.9M | $-3.8M | $-24.9M | $-31.1M | $-15.4M | -- | -- | ||
| Pre-Tax Income | $-9.9M | $-3.8M | $-24.9M | $-31.1M | $-15.4M | $-17.2M | $-16.7M | ||
| INCOME TAX | |||||||||
| Tax Provision | $-1.9M | $-689.0K | $-2.2M | -- | -- | $-449.0K | $-4.9M | ||
| NET INCOME | |||||||||
| Net Income | $-8.0M | $-3.1M | $-22.7M | $-27.9M | $-19.0M | $-16.8M | $-11.9M | ||
| Net Income (Continuing Operations) | $-8.0M | $-3.1M | $-22.7M | $-27.9M | $-19.0M | $-16.8M | $-11.9M | ||
| Net Income (Discontinued Operations) | $-8.0M | $-3.1M | $-22.7M | $-27.9M | $-19.0M | $-16.8M | $-11.9M | ||
| Net Income (Common Stockholders) | $-8.0M | $-3.1M | $-22.7M | $-27.9M | $-19.0M | $-16.8M | $-11.9M | ||
| TOTALS | |||||||||
| Total Expenses | $5.5M | $3.7M | $19.2M | $13.2M | $13.8M | $18.0M | $15.8M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $318.9M | $341.2M | $169.1M | $97.9M | $101.5M | $102.5M | -- | ||
| Average Shares Outstanding (Diluted) | $318.9M | $341.2M | $169.1M | $97.9M | $126.5M | $102.5M | -- | ||
| Shares Outstanding | $682.3M | $341.6M | $194.6M | $102.3M | $102.3M | $111.5M | $111.5M | ||
| Basic EPS | $-0.02 | $-0.03 | $-15.46 | $-0.24 | $-0.15 | $-0.17 | -- | ||
| Basic EPS (Continuing Operations) | $-0.02 | $-0.03 | $-15.46 | $-0.24 | -- | $-0.17 | -- | ||
| Diluted EPS | $-0.02 | $-0.03 | $-15.46 | $-0.24 | $-0.15 | $-0.17 | -- | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-0.17 | -- | ||
| OTHER METRICS | |||||||||
| Acquired In Process Rn D Income | $-4.4M | $-6.2M | $-11.2M | -- | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | -- | $-4.5M | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | $-4.5M | -- | -- | -- | ||
| Gain On Sale Of Business | $-21.0K | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | $2.7M | -- | -- | -- | -- | ||
| Net Income From Other Gains Losses | -- | -- | $2.2M | $3.2M | -- | -- | -- | ||
| Other Gand A | $4.4M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TLSA | $1.82 | 0% | 268.77K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Tiziana Life Sciences Ltd Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW